Innovotech Inc
XTSX:IOT
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
|
Innovotech Inc
XTSX:IOT
|
14m CAD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
204.9B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
153.2B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
46.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.4B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
36.9B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
31.9B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.3B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.8B USD |
Loading...
|
Market Distribution
| Min | -10 058.3% |
| 30th Percentile | 20.4% |
| Median | 33.6% |
| 70th Percentile | 50.5% |
| Max | 717.4% |
Other Profitability Ratios
Innovotech Inc
Glance View
Innovotech Inc. provides solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada, the United States and internationally. The company is headquartered in Edmonton, Alberta. The company went IPO on 2003-05-28. The firm's contract research services cover various applications, including implanted devices antimicrobial testing; antibiotic and biocide efficacy screening; agricultural diseases, food safety; dental biofilms; waterline and pipeline fouling; regulatory submission packages; consulting services; and third-party validations. The firm's assays and services include biofilm antimicrobial testing, planktonic antimicrobial testing, aerobic and anaerobic microorganisms as well as bacterial spores. Its products include InnovoSIL Antimicrobial Products, The MBEC Assay, and Agress and AgreGuard. InnovoSIL is a family of antimicrobial agents suited to coating onto or incorporation into medical devices. The MBEC assay is biofilm growth device. Agress and AgreGuard is a seed treatment and plant spray.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Innovotech Inc is 47.1%, which is below its 3-year median of 61.9%.
Over the last 3 years, Innovotech Inc’s Gross Margin has decreased from 72.1% to 47.1%. During this period, it reached a low of 47.1% on Oct 30, 2025 and a high of 72.1% on Aug 30, 2022.
